WELT

News

Can Pear bud again? Ex-CEO McCann bids for assets

Digital therapeutics (DTx) company Pear Therapeutics may be heading for a new lease of life, if a plan by former chief executive Corey McCann pays off.

News

South Korea approves its first digital therapeutic

An app to treat insomnia has become the first DTx approved for marketing in South Korea.

News

Tenax trounced by phase 3 heart failure readout

Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks